2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Biological Processes, Immune Mechanism, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Diseases, Bleeding and Clotting, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Research, AML, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

5982 Model estimated fludarabine exposure and clinical outcomes following allogeneic transplantation with post-transplant cyclophosphamide

Selin Merih Urlu, MD, Jim Westholder2, Qing Cao, MS3, Christopher D Graham, MD4, Punita Grover, MD5, Joseph Norton, D.O.6, Roy L Kao, MD7, Cameron McDonald-Hyman, MD, PhD8, Veronika Bachanova, MD, PhD9, Daniel Weisdorf, MD10, Mark B. Juckett, MD, MHCM11
1 University of Minnesota, Minneapolis, Minnesota, United States
2 University of Minnesota, Minneapolis, Minnesota, United States
3 University of Minnesota, Minneapolis, Minnesota, United States
4 University of Minnesota, Minneapolis, Minnesota, United States
5 University of Minnesota, Minneapolis, Minnesota, United States
6 University of Minnesota, Minneapolis, Minnesota, United States
7 University of Minnesota, Minneapolis, Minnesota, United States
8 University of Minnesota, Minneapolis, Minnesota, United States
9 University of Minnesota, Minneapolis, Minnesota, United States, University of Minnesota, Minneapolis, Minnesota, United States
10 University of Minnesota, Minneapolis, Minnesota, United States
11 University of Minnesota, Minneapolis, Minnesota, United States

Background

Fludarabine (Flu) is a key component of conditioning regimens for allogeneic hematopoietic cell transplantation (alloHCT). Flu exposure (excess or insufficient) may adversely affect transplant outcomes, suggesting a potentially narrow therapeutic window. We hypothesized that excessive fludarabine PK exposure is associated with inferior outcomes in patients receiving post-transplant cyclophosphamide (PTCy)–based GVHD prophylaxis, and investigated an optimal therapeutic exposure.

Methods

We retrospectively studied all patients who underwent alloHCT at the University of Minnesota between April 2018 and November 2025. Fludarabine exposure (area under the curve [cAUC]) was estimated using the previously validated Langenhorst population PK model incorporating actual body weight, serum creatinine, age, height, and sex. Cumulative exposure was calculated as the total administered dose divided by estimated clearance. Patients were categorized into four cAUC groups (<23, 23–<26, 26–<28, and 28–<38 mg h/L) and an additional control group. Exploratory outcome-associated cutoffs were identified using recursive partitioning. OS and PFS were estimated using Kaplan–Meier methods, while competing-risk methods were used for relapse, TRM, and GVHD.

Results

We evaluated 419 alloHCT recipients treated with PTCy-based GVHD prophylaxis, including 250 patients who received Flu-based conditioning and 169 in the control group. AML (44.6%), ALL (18.1%), and MDS (14.8%) were the most common indications. Flu-exposed patients received MA or RIC conditioning, with protocol-based Flu dosing consisting primarily of 30 mg/m² for 5 doses (total, 150 mg/m²) or 40 mg/m² for 4 doses (total, 160 mg/m²); other or renally adjusted doses were used when indicated. Among Flu-exposed patients, most received reduced-intensity conditioning (RIC, 64.4%) and cAUC values demonstrated a broad distribution within the study population, ranging from approximately 16 to 38 mg h/L. Using an exploratory OS-derived recursive-partitioning cutoff, we defined two Flu exposure groups: lower exposure (cAUC <26.9 mg·h/L; n=156, 62.4%) and higher exposure (cAUC ≥26.9 mg·h/L; n=94, 37.6%). Compared with the lower-exposure group (low), patients in the higher-exposure group (high) were older, more frequently male, and more likely to have received sirolimus-based GVHD prophylaxis.

One-year TRM was 6% (95% CI, 2–10%) in the low compared with 3% (95% CI, 0–7%) in the high group (p=0.30). One-year OS was 83% (95% CI, 76–88%) in low versus 93% (95% CI, 86–97%) in the high (p=0.02). One-year PFS was not significantly different between the low- and high-exposure groups (73% [95% CI, 65–79%] vs 79% [95% CI, 69–86%], respectively; p=0.27) while 1-year relapse incidence was similar (17% [95% CI, 10–25%] vs 21% [95% CI, 14–28%]; p=0.47).

There were no significant differences between the lower- and higher-exposure groups in 6-month GVHD incidence (acute grade II-IV 17% vs 17%; p=0.95), (grade III–IV 8% vs 6%; p=0.54), or chronic GVHD (15% vs 19%; p=0.39). In an exploratory univariable analysis, chronic GVHD was more frequent with MMF/sirolimus/PTCy than with tacrolimus/MMF/PTCy prophylaxis (18% vs 8%; p<0.01). Apart from the OS difference identified using the exploratory data-derived cutoff, Flu exposure was not significantly associated with PFS, relapse, or TRM.

Conclusion

In this cohort of alloHCT recipients receiving PTCy-based GVHD prophylaxis, PFS, relapse, TRM, and GVHD were similar across a broad range of Flu exposures measured by cAUC, with little overall difference in clinical outcomes. The OS difference identified using an exploratory data-derived cutoff requires validation and does not define an optimal therapeutic exposure threshold.

Selin Merih Urlu, MD: No relevant conflicts of interest to declare.